In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
What are the challenges surrounding clinical trial design for genetic therapies in terms of neurodegenerative diseases? What technological advances could help bring these therapies to the clinic more quickly? Find out in our video interview with Sarah Tabrizi.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
As part of our Spotlight on organoids, we carried out a survey to gain an insight into how organoids are being used as a research tool in the lab, the challenges involved in organoid research and what researchers thought about the terms ‘mini-brains’ and ‘brains in a dish’. Find out the results in this informative infographic.
In a revolutionary approach, Cognetivity (London, UK) have created a new test for detecting dementia and Alzheimer’s disease by focusing on image cognition and the brain’s ability to analyze visual information.
The BioTechniques editorial team talk to Jenny Straiton about her recent Tech News piece on cerebral organoids and the history of neuroscience.
In this video, Marc describes what his favorite aspect in research has been so far and offers advice for those interested in studying CTE.
We had the pleasure of filming a joint seminar from the Michael J Fox Foundation and Abcam on biomarkers of neuroinflammation in Parkinson’s disease. Discover more about this in our video, with timepoints for each slide included.
In this video, Marc Goldfinger provides us with an overview of his work on CTE and boxer’s brains, including why CTE is of increasing public interest.